Trial Search Results

A Study of HGS1029 (AEG40826-2HCl) in Subjects With Advanced Solid Tumors

The purpose of this study is to evaluate the safety and tolerability of HGS1029 in subjects with advanced solid tumors and to determine a phase 2 dose.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Human Genome Sciences Inc.


  • Drug: HGS1029


Phase 1


Inclusion Criteria:

   - Confirmed advanced solid malignancy

   - Life expectancy of at least 3 months

   - Age 18 years or older

   - Acceptable liver function

   - Acceptable renal function

   - Acceptable hematologic status

Exclusion Criteria:

   - Received investigational (not yet approved by a regulatory authority)agent within 4
   weeks before enrollment.

   - Received non-investigational agent within 3 weeks before enrollment.

   - Progressive CNS involvement including the need of corticosteroids

   - Pregnant or breast-feeding women

   - Active, uncontrolled bacterial, viral, or fungal infections within 2 weeks of Cycle 1
   Day 1

   - Known HIV infection

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study


Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Cancer Clinical Trials Office
Not Recruiting